User: Guest

  

The global market for Cancer Therapies is projected to reach US$220.5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease. Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities.

Against the backdrop of tumor diversity, the universal "one size fits all" therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side-effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancer`s diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism. For instance, scientists are close to identifying the key molecule involved in cancer`s mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called "alternative splicing`. Aberrations in alternative splicing are linked to cancer`s progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancer`s biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide.

DOMAIN EXPERT ENGAGEMENTS

Number of executives repeatedly engaged by snail & email outreach*

POOL + OUTREACH

8489

Interactions with Platform & by Email *

INTERACTIONS

1188

Unique # Participated *

PARTICIPANTS

253

Responses Validated *

VALIDATIONS

48

* Platform engagements are dynamic. Stats are published quarterly.


  •  CODE

  •  PAGES

  •  DATE

  •  PRICE

    $

  •  DATA EXHIBITS

    125


TABLE OF CONTENTS


   Pages :    | $

   Study Reliability and Reporting Limitations.....I-1  
   Disclaimers.....I-2
Data Interpretation & Reporting Level.....I-2
  
   Quantitative Techniques & Analytics.....I-3
Product Definitions and Scope of Study.....I-3
Immunotherapy.....I-3
  
   Targeted Therapy.....I-4
Hormonal Therapy.....I-4
Chemotherapy.....I-4
  
   Cancer Therapies: An Outlook.....II-5
US Retains Global Dominance.....II-5
Immunotherapies Lead the Suite, Targeted Therapies to Claim the Top Spot.....II-5
1$100
   Cancer Therapies: A Review.....II-61$100
   Enduring Success of Top Drug Makers Makes Oncology Area More Endearing.....II-7
Table 1: Select Leading Cancer Therapies Worldwide by Revenues: 2006-2010 (includes corresponding Graph/Chart).....II-7
1$350
   Monoclonal Antibodies Open Up a New Era in Cancer Treatment.....II-8
Table 2: Leading Monoclonal Antibodies Worldwide by Revenues: 2009 & 2010.....II-8
1$350
   Biotherapies to Drive Growth in Cancer Therapy Market.....II-9
Biotech Cancer Therapies Yet to Overcome Teething Issues.....II-9
Oncology Drugs – the Leader in the Global Pharma Pipeline.....II-9
1$100
   Table 3: Cancer Therapies Market: Number of Approved/Marketed and Pipeline Drugs by Select Cancer Types as of 2010 (includes corresponding Graph/Chart).....II-10
New Cancer Therapies Appear Over the Horizon.....II-10
1$350
   Late Stage Promising Drugs in Cancer Therapy.....II-11
US Ahead in Approving Cancer Drugs.....II-11
1$100
   FDA-Approved Oncology Drugs in Recent Years (2008-2011).....II-121$100
   New Cancer Drugs Approved by EMA in 2009 and 2010.....II-131$100
   Competition Set to Rise in Cancer Therapy.....II-14
Table 4: Leading Companies in the Global Oncology Therapy Market (2010): Percentage Breakdown of Revenues for Roche, Novartis, Amgen, AstraZeneca, sanofi-aventis and Celgene (includes corresponding Graph/Chart).....II-14
Competition Intensifies in the Cancer Biotherapy Segment.....II-14
1$350
   Innovations in Cancer Drug Delivery: A Key Factor in Product Differentiation.....II-15
Follow-On Indications Flock Oncology Pipeline.....II-15
Personalized Medicine: Gain in Importance.....II-15
Combination Therapy: A Double Whammy Success.....II-15
1$100
   Patent Expiries of Branded Drugs to Trigger Generic Competition.....II-16
Rising Investments Bring in New Troubles for Drug Makers.....II-16
Emerging Challenges in Cancer Drug Development.....II-16
1$100
   Select Drugs Receiving Complete Response Letters from the FDA in 2010.....II-17
Drug Failures – Deterring Prospects of New Therapies.....II-17
1$100
   Failures in Phase III Clinical Trials of Oncology Drugs in 2010.....II-18
Drug Withdrawals Hurt Pharma Companies.....II-18
1$100
   Growth Drivers In a Capsule.....II-19
Rise in Cancer Incidences & Access to Modern Therapeutics Foster Growth.....II-19
Demographics & Lifestyles Raise the Risk of Cancer.....II-19
Cancer Prone Sites based on Age.....II-19
1$100
   Table 5: Population of People Aged More than 65 Years in United States for the years 2000, 2010, and 2020 (includes corresponding Graph/Chart).....II-20
Unmet Needs Leave Scope for Further Research and Development.....II-20
Low Entry Barriers in Cancer Research Encourages Breakthrough Developments.....II-20
Increasing Investments by National Health Authorities.....II-20
1$350
   Efficiency & High Prices Magnetize Manufacturers.....II-21
Supportive Cancer Drugs Contribute to Growth.....II-21
Improved Screening, Diagnosis & Patient Survival Rates Trigger Growth.....II-21
Molecular Imaging of Cancer: Critical in Improving Patient Outcomes.....II-21
1$100
   Innovations, Improvements, and Approvals Propel Growth.....II-221$100
   Growth Restraints.....II-23
High Prices of Targeted Therapies Act as a Speed Breaker.....II-23
Table 6: Estimated Average Monthly Cost of Select Leading Cancer Drugs in the US as of 2008.....II-23
1$350
   Limited Tumor Specificity and Toxicity.....II-24
Complicated Treatment Protocols: A Major Stumbling Block in Patient
  Compliance.....II-24
Reduced Smoking.....II-24
Reimbursement and Coverage Remains a Major Challenge.....II-24
1$100
   Changes in Reimbursement Policies Influence Market Prospects.....II-25
Multiple Drug Resistance.....II-25
Stringent Regulations Delay Market Approval.....II-25
1$100
   Challenges Encountered in Clinical Trials.....II-26
High Development Costs Retracts Manufacturers in Developing Countries.....II-26
1$100
   Current and Future Analysis.....II-27
Targeted Therapy – An Overview.....II-27
Targeted Therapy: The New Frontier of Cancer Treatment.....II-27
1$100
   List of Select Approved Targeted Therapy Drugs by Indication.....II-281$100
   Select Targeted Anti-Cancer Therapies in Late-Stage (Phase III) Clinical
  Development.....II-29
Table 7: Targeted Therapies Market Worldwide (2010): Percentage Breakdown of Targeted Therapeutic Drugs under Various Stages of Development (includes corresponding Graph/Chart).....II-29
1$350
   Table 8: Molecular Targeted Therapies Worldwide: Percentage Breakdown of Molecular Targeted Therapies under Pipeline by Drug Class as of 2010 (includes corresponding Graph/Chart).....II-30
Types of Targeted Therapy.....II-30
Tyrosine Kinase Inhibitors.....II-30
1$350
   List of Approved Tyrosine Kinase Inhibitors.....II-31
Angiogenesis Inhibitors.....II-31
List of Approved Angiogenesis Inhibitors.....II-31
Proteasome Inhibitors.....II-31
Multi-Targeted Drugs.....II-31
1$100
   Select Approved Multi-Targeted Drugs in Targeted Cancer Therapy.....II-32
Gene Therapy.....II-32
1$100
   Current and Future Analysis.....II-33
Table 9: Global Market for Immunotherapy (2007 and 2012): Percentage Breakdown of Revenues by Drug Class - Monoclonal Antibodies, Biological Response Modifiers, Vaccines, and Other Immunotherapy Products (includes corresponding Graph/Chart).....II-33
1$350
   Immunotherapy Treatment Strategies.....II-34
Vaccination with Dendritic Cells Pulsed With Tumor Antigens.....II-34
Gene Technique-Based Immunotherapy.....II-34
Inhibiting Tumor-Induced Immunosuppression.....II-34
Immunostimulants.....II-34
Use of Monoclonal Antibodies.....II-34
Immunotoxins.....II-34
Radioimmunotherapy.....II-34
T Cells based Therapy.....II-34
Types of Cancer Immunotherapy Drugs.....II-34
1. Monoclonal Antibodies.....II-34
1$100
   Select Immunotherapy-based Monoclonal Antibodies Approved for Cancer
  Treatment.....II-35
2. Biological Response Modifiers (BRMs).....II-35
3. Vaccines – A Promising Future Area of Cancer Therapeutics.....II-35
1$100
   Therapeutic Cancer Vaccines: Harnessing the Immune System to Fight Cancer.....II-36
Cancer Vaccine Strategies.....II-36
RNA-Loaded Dendritic Cells Cancer Vaccine:.....II-36
Liposomal Vaccine:.....II-36
Vaccine Targeting Pregnancy Hormone:.....II-36
Viral Vector Vaccine:.....II-36
1$100
   Listeria-Based Vaccine:.....II-37
Telomerase Targeting Vaccine:.....II-37
Cancer Vaccine Makes Debut in the US, Finally.....II-37
Approved Therapeutic Cancer Vaccines Worldwide.....II-37
Cancer Vaccine Pipeline Shows Significant Promise.....II-37
1$100
   World Cancer Vaccine Pipeline as of 2011.....II-38
Long-Drawn Journey to Success Offers New Lessons for Drug Makers.....II-38
4. Other Immunotherapy Products.....II-38
1$100
   Current and Future Analysis.....II-39
Hormonal Therapy – An Overview.....II-39
Hormonal Therapy Strategies.....II-39
Hormone Synthesis Inhibitors.....II-39
Aromatase Inhibitors.....II-39
1$100
   GnRH Analogs.....II-40
Hormone Receptor Antagonists.....II-40
Selective Estrogen Receptor Modulators (SERMs).....II-40
Antiandrogens.....II-40
Hormone Supplementation.....II-40
Progestagens and Androgens.....II-40
Estrogens.....II-40
Somatostatin Analogs.....II-40
Shifting Therapeutic Preferences.....II-40
1$100
   Table 10: Global Market for Antihormonal Therapy (2005 and 2014): Percentage Breakdown of Revenues by Drug Class - LHRH Analogs, Aromatase Inhibitors, Anti-androgens, Anti-estrogens, and Other Hormone Antagonists (includes corresponding Graph/Chart).....II-41
Drug Classes in Hormone Therapy.....II-41
Drugs Used in Hormone Therapy and Their Uses.....II-41
1$350
   Side-Effects Associated with the Use of Various Drugs in Hormone Therapy.....II-421$100
   Current and Future Analysis.....II-43
Chemotherapy – An Overview.....II-43
1$100
   The Chemotherapy Market Space – An Overview.....II-44
Chemotherapy Market Cluttered with Numerous Players.....II-44
Chemotherapy Drugs Require Careful Handling.....II-44
1$100
   Types of Chemotherapy.....II-45
Adjuvant Chemotherapy.....II-45
Combined Modality Chemotherapy.....II-45
Neoadjuvant Chemotherapy.....II-45
Palliative Chemotherapy.....II-45
Chemotherapy Drug Classes.....II-45
Nucleoside Analogues.....II-45
Alkylating Agents.....II-45
Antimetabolites.....II-45
Nitrosoureas.....II-45
Steroid hormones.....II-45
Platinum Containing Compounds.....II-45
Folate antagonists.....II-45
Microtubule-targeting agents.....II-45
Topoisomerase inhibitors.....II-45
Risks Associated with Chemotherapy.....II-45
1$100
   When Chemotherapy Fails .....II-461$100
   Cancer: A Major Health Crisis in the Modern World.....II-47
Table 11: Cancer Causes in Developed and Developing Countries (2010): Percentage Breakdown by Risk Factors - Diet or Nutrition, Infections, Tobacco, and Other Factors (includes corresponding Graph/Chart).....II-47
1$350
   Types of Cancers.....II-48
Prostate Cancer.....II-48
Select FDA-Approved Prostate Cancer Drugs.....II-48
1$100
   Select Prostate Cancer Agents in Mid- & Late-Stage Clinical Development.....II-49
Table 12: Revenues of Select Leading Prostate Cancer Drugs: 2006-2010 (includes corresponding Graph/Chart).....II-49
1$350
   Breast Cancer.....II-50
Select FDA Approved Breast Cancer Drugs.....II-50
1$100
   Table 13: Breast Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-51
Cervical Cancer.....II-51
Colorectal Cancer.....II-51
1$350
   Select FDA-Approved Colorectal Cancer Drugs.....II-52
Table 14: Colorectal Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-52
1$350
   Lung Cancer.....II-53
Select FDA-Approved Non-Small Cell Lung Cancer Drugs.....II-53
1$100
   Table 15: Lung Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-54
Renal Cancer.....II-54
Select FDA-Approved Renal Cell Carcinoma Drugs.....II-54
Skin Cancer.....II-54
1$350
   Table 16: Skin Cancer/Melanoma Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-55
Pancreatic Cancer.....II-55
Table 17: Pancreatic Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-55
1$350
   Non-Hodgkin’s Lymphoma.....II-56
Leukemia.....II-56
Bladder Cancer.....II-56
Table 18: Bladder Cancer Drug Pipeline: Number of Drugs by Development Stage as of 2010 (includes corresponding Graph/Chart).....II-56
Endometrial Cancer.....II-56
1$350
   Cancer Incidence – Statistics on New Cases.....II-57
Table 19: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart).....II-57
1$350
   Table 20: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart).....II-58

Table 21: Cancer Incidence in Upper Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-58
1$350
   Table 22: Cancer Incidence in Lower Middle Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-591$350
   Table 23: Cancer Incidence in High Income Countries by Site: 2009 (includes corresponding Graph/Chart).....II-601$350
   Merck Receives Approval for EMEND® IV in Canada.....II-61
Sun Pharma Receives FDA Approval for Docefrez.....II-61
Amgen Secures FDA Approval for Denosumab.....II-61
Eisai Receives FDA Approval for Halaven.....II-61
1$100
   Dendreon Corporation Secures FDA Approval for Provenge.....II-62
GlaxoSmithKline Secures Accelerated Approval from FDA for TYKERB.....II-62
Roche Receives European Commission Approval for Herceptin in Metastatic Gastric Cancer
  Treatment.....II-62
Gloucester Pharmaceuticals Receives FDA Approval for Istodax.....II-62
1$100
   YM BioSciences Gains Marketing Approval for Nimotuzumab in Mexico.....II-63
Bristol-Myers and ImClone Receives FDA Approval for Erbitux Labeling Revisions.....II-63
Abraxis Receives Approval for Abraxane in Quebec, Canada.....II-63
Genentech Receives FDA Approval for Avastin.....II-63
ABRAXANE Gains Marketing Approval in Korea, Australia and Other Countries.....II-63
1$100
   GlaxoSmithKline's Cervarix Finds Place in UK National Immunization Programme.....II-64
Biogen Idec and Elan Commence Clinical Trial of TYSABRI.....II-64
1$100
   Calistoga Pharmaceuticals Starts Phase I Clinical Trial of CAL-101.....II-65
Progen Pharmaceuticals Continues Phase 1 Development of PG-11047.....II-65
GlaxoSmithKline Receives Conditional EU Approval for Marketing Lapatinib.....II-65
Roche’s Xeloda Gains EU Approval for Use in Colorectal Cancer Treatment.....II-65
Genentech Secures FDA Approval for Avastin.....II-65
1$100
   EU Approves Four Biosimilar Versions of Neupogen.....II-66
Russia Approves Oncophage for Kidney Cancer Treatment.....II-66
Eisai to Start Clinical Testing of MORAb-028.....II-66
Threshold Pharmaceuticals Starts Phase I/II Clinical Trials of TH-302.....II-66
AVEO Commences Phase 1b Clinical Study of AV-951 and FOLFOX6.....II-66
GSK’s Tykerb Receives USFDA Approval.....II-66
1$100
   Seattle Genetics Initiates Phase 1b Clinical Trials of SGN-40 with Gemzar and
  Rituxan.....II-67
S*Bio Initiates Phase I Clinical Trials of SB1518.....II-67
Merck Serono Initiates Phase III Trials of Cladribine.....II-67
BioCurex Receives Patent for RECAF Technology Applications.....II-67
Chidamide/HBI-8000 Completes Phase I Clinical Trials in China.....II-67
1$100
   AVEO Initiates Phase I Trials of AV 299.....II-68
Exelixis Completes Phase I Trials of XL765.....II-68
Infinity Pharmaceuticals Starts Phase I Clinical Trial of IPI-926.....II-68
Cell Genesys Terminates its VITAL-1 Phase 3 Trial of GVAX.....II-68
GTx Completes Phase II Clinical Trials of Ostarine.....II-68
Imclone Awaits Approval for Erbitux from US Medicine Regulator.....II-68
1$100
   Kuhnil and Daiichi Sankyo Initiate Phase II Clinical Trial of Nimotuzumab.....II-69
Peplin Starts Phase III Clinical Trials of PEP005 Gel.....II-69
ERBITUX Receives Marketing Approval in Japan.....II-69
Progenics Starts Phase I Clinical Study of PSMA ADC.....II-69
FDA Awards Orphan Drug Designation for the Use of Stem Cell Technology in Bone Marrow
  Transplantations.....II-69
1$100
   Roche, OSI and Chugai Receive Approval for Tarceva in Japan.....II-70
Eisai Receives FDA Approval for ONTAK®.....II-70
Genmab Terminates the Development of HuMax-CD4.....II-70
Teva Pharmaceutical Acquires EU Authorization to Market Neutropenia Drug.....II-70
Novartis’ Everolimus Awaits Approvals from US FDA, Swissmedic, and EMEA.....II-70
1$100
   Abraxis BioScience, AstraZeneca, and NCCN to Conduct Anti-cancer Drug Studies.....II-71
Sanofi-Aventis Receives Japanese Approval for Taxotere® Injection.....II-71
Roche’s Avastin Bags European Approval for Renal Cancer Treatment.....II-71
Roche Announces European Approval of Herceptin.....II-71
GSK’s Hycamtin Obtains FDA Approval.....II-71
1$100
   Avastin Receives European Approval for Breast Cancer Treatment.....II-72
Roche’s Tarceva Obtains European Approval.....II-72
Roche’s NeoRecormon Gains European Approval.....II-72
Northwest Biotherapeutics’ DCVax-Brain Gains Swiss Approval.....II-72
Alfacell’s ONCONASE Receives Orphan Drug Designation from US.....II-72
1$100
   Cougar Biotechnology Commences Phase II Trial of CB7630.....II-73
Lorus Therapeutics Receives Orphan Drug Designation for its LOR-2040.....II-73
Merck Serono Receives EU Approval for mCRC Treatment With Erbitux.....II-73
MGI PHARMA and HELSINN Receive FDA Approval For Aloxi.....II-73
FDA Grants Approval for Sutent, a Kidney and Gastrointestinal Cancer Drug.....II-73
1$100
   Wyeth Pharmaceuticals’ TORISEL Receives FDA Approval.....II-74
Dabur Pharma Acquires FDA Approval for Paclitaxel Injection.....II-74
EUSA’s CAPHOSOL Finds Application in Treating Oral Mucositis.....II-74
European Commission Approves Amgen’s Vectibix for Metastatic Colorectal Cancer.....II-74
GPC Biotech Starts Phase 2 Trials of Satraplatin plus with Tarceva.....II-74
1$100
   FDA Approves Vectibix as Treatment for Metastatic Colorectal Cancer.....II-75
FDA Approves IND Indication for CYT-500 of Cytogen.....II-75
FDA Clears Rituxan for New Indications.....II-75
Epeius Receives BFAD Approval for Expanded Access Program for Rexin- G.....II-75
1$100
   BioMedicines Initiates Phase 1b Study of Biomed 101.....II-76
Avastin Obtains FDA Approval for Treating Recurrent Colorectal Cancer.....II-76
Genentech’s Herceptin Gains FDA Nod for Treating Early stage Cancer after
  Surgery.....II-76
1$100
   Epeius Starts Phase I and II Trials of the New Tri-Rex Vaccination Protocol.....II-77
Sonus Begins Phase 1 Clinical Trial of TOCOSOL® Camptothecin.....II-77
Dynavax Begins Phase 1 Clinical Trial of TLR9 agonist Combined with Chemotherapy
  Regimen.....II-77
Morphotek’s MORAb-009 Receives Orphan Drug Designation.....II-77
1$100
   Morphotek’s MORAb-003 Receives Orphan Drug Status from the US FDA.....II-78
Morphotek Grants FDA Approval of the IND for MORAb-009.....II-78
MannKind Receives IND Clearance for MKC1106-PP Immunotherapy.....II-78
1$100
   Pharmexa Initiates Phase II trials of GV 1001.....II-79
Wyeth Pharmaceuticals Declares Discontinuation of Phase III Clinical Trials for
  Temsirolimus.....II-79
OXiGENE Announces Clinical Trials of CA4P.....II-79
Glaxo SmithKline’s Hycamtin Gains FDA Approval for Treating Cervical Cancer.....II-79
1$100
   Cell Genesys Announces the Initiation of Amplified Phase I Trial of CG0070.....II-80
Genentech’s Avastin Receives FDA Approval for Lung Cancer Treatment.....II-80
Vorinostat Acquires FDA Approval for Skin Cancer Treatment.....II-80
Callisto Launches the First Clinical Trial of Landmark Discovery, L-Annamycin for
  ALL.....II-80
1$100
   Shanghai Sunway Biotech’s H101 Receives Marketing Approval in China.....II-81
Northwest Biotherapeutics Gains Patent for CXCR4.....II-81
1$100
   Biocon’s Cancer Drug Initiates Phase II Trials.....II-821$100
   Dr Reddy's Laboratories Introduces Peg-Grafeel Injection in India.....II-83
Sanofi-Aventis Introduces Jevtana (cabazitaxel) Injection in the US.....II-83
Natco Pharma Introduces Anastrazole for Breast Cancer in US.....II-83
Dr Reddy's Laboratories Introduces Anastrazole Tablets in US.....II-83
Zynx Health Introduces Zynx OncologyCare.....II-83
1$100
   Ferring Pharmaceuticals Introduces FIRMAGON® in Europe.....II-84
GSK Launches Cervarix in Singapore.....II-84
Abeome Launches New Stem Cell Monoclonal Antibody.....II-84
Dabur Pharma Launches a New Drug Delivery System, Nanoxel.....II-84
1$100
   Epeius Biotechnologies Develops New Targeted Anti-Cancer Drugs.....II-85
Monash University Scientists Develop siRNA for Cancer Treatment.....II-85
Cytogen Introduces SOLTAMOX™, the First Hormonal Breast Cancer Therapy.....II-85
1$100
   BioLineRx Acquires License Rights of BL-7030 from Algen.....II-86
Glenmark Establishes New Manufacturing Plant in Argentina.....II-86
Centella Therapeutics Signs Licensing Agreement with Auckland UniServices.....II-86
Cephalon Enters a Definitive Merger Agreement with Gemin X.....II-86
1$100
   IRX Therapeutics Enters a New Research Collaboration.....II-87
RXi Pharmaceuticals Acquires Apthera.....II-87
Gilead Sciences to Enter into Collaboration with Yale School of Medicine for Cancer
  Therapies.....II-87
Sage Bionetworks Forms Alliance with AstraZeneca.....II-87
Amgen Acquires BioVex Group.....II-87
1$100
   AREVA Inks Cooperative Research Agreement with INSERM.....II-88
Dendreon Secures FDA Approval for New Jersey Manufacturing Facility.....II-88
Celgene Acquires Abraxis BioScience.....II-88
HUYA Partners with Quintiles to Co-Develop HBI-8000 Cancer drug (US/China).....II-88
China PharmaHub Signs Agreement with Global Player in Precision Glass
  Technology.....II-88
1$100
   Immunotope Partners with Midatech Group to Form Syntara.....II-89
ChromoCure Acquires GRG.....II-89
Qatar National Cancer Society and SAH Global Sign MoU.....II-89
Neogenix Gains FDA Orphan Drug Designation for Ensituximab.....II-89
1$100
   ImmunoGen Gains Orphan Drug Status for Lorvotuzumab Mertansine.....II-90
Syngene International Enters Into Agreement with Endo Pharmaceuticals.....II-90
Immunovaccine and Oncothyreon Ink Research Agreement.....II-90
OncoGenex Inks Licensing Agreement with Teva Pharmaceutical.....II-90
NanoCarrier Enter into Comprehensive Joint Research Agreement with MEDINET.....II-90
1$100
   VaxOnco Acquires Intellectual Property Rights for Onyvax-P.....II-91
Novation Pharmaceuticals and Cancer Therapeutics Enter into Collaboration.....II-91
Cancer Therapeutics Signs Letter of Intent with NanoTherapies.....II-91
sanofi-aventis Acquires BiPar Sciences.....II-91
1$100
   IBt Bebig, Rusnanotech and Santis Form Joint Venture for Cancer Treatment.....II-92
Roche Acquires Genentech.....II-92
AstraZeneca Enters into Collaboration with Merck.....II-92
Cytopia Merges with YM BioSciences.....II-92
1$100
   Aveo Pharmaceuticals and Biogen Idec Sign Definitive Agreement.....II-93
Opsona Therapeutics Inks Research and Collaboration Agreement with CSL.....II-93
Micromet Signs Agreement with Lonza.....II-93
Clavis Pharma Enters Into Agreement with Clovis Oncology.....II-93
1$100
   Abraxis Takes Over Platco and Shimoda.....II-94
WEHI Collaborates with Abbott and Genentech.....II-94
Novartis Inks a Production Deal with Lonza.....II-94
1$100
   Roche Takes Over UK-Based Biotech Company, Piramed.....II-95
Pfizer Acquires Encysive.....II-95
Eden Biodesign Inks a Marketing Services Deal with Human Genome Sciences.....II-95
FivePrime Join Hands with Pfizer for Cancer and Diabetes Research.....II-95
1$100
   Sanofi-Aventis and Dyax Ink Two Antibody Pacts.....II-96
Pfizer and AVANT Ink a Global Licensing Agreement for CDX-110.....II-96
1$100
   Takeda Inks an Exclusive Partnership Agreement with Amgen.....II-97
Genentech and Roche Ink a Licensing Agreement with Glycart.....II-97
Bristol-Myers Squibb Acquires Kosan Biosciences.....II-97
Nabi Biopharmaceuticals Collaborates with NIAID.....II-97
1$100
   Pfizer to Acquire Serenex.....II-98
Morphotek Signs an Agreement with Pivotal BioSciences.....II-98
GE Healthcare Inks a Three-Year Agreement with Eli Lilly.....II-98
ArQule Signs Two Agreements with Daiichi Sankyo.....II-98
1$100
   Circadian Completely Acquires Vegenics Limited.....II-99
Lpath Inks an Accord with Merck Serono.....II-99
Topex Expands its Distribution Deal with Therapy Remarketing.....II-99
Unibioscreen Inks a Partnership Agreement with Drais Pharmaceuticals.....II-99
Avant Immunotherapeutics Becomes Celldex Therapeutics.....II-99
1$100
   Abraxis Enters into Definitive License Agreements with ProMetic Life Sciences.....II-100
Biovest International to Receive US$1.6 Million Funding for Biomedical
  Research.....II-100
Access Completes the Acquisition of Somanta.....II-100
Clinical Data Inks an Agreement to Take Over Avalon Pharmaceuticals.....II-100
1$100
   EUSA Pharma Acquires Cytogen Corporation.....II-101
Oncologic Merges with Triton BioSystems.....II-101
Eli Lilly Takes Over ImClone Systems.....II-101
CEL-SCI Establishes a New Manufacturing Unit.....II-101
1$100
   ZaBeCor Establishes Biothorpe Pharmaceuticals, a New Subsidiary.....II-102
Takara Bio Signs a Research Agreement with a Chinese University.....II-102
Shanghai Roche Expands its MabThera Marketing Activities.....II-102
Merck Completes the Acquisition of Majority Stake in Serono.....II-102
Merck Enters into Licensing and Collaboration Agreement With Idera.....II-102
1$100
   Sanofi-Aventis Inks a Global Licensing Deal with Oxford BioMedica.....II-103
WEHI to Collaborate with Genentech and Roche.....II-103
AstraZeneca Acquires MedImmune.....II-103
Antisoma Enters into a Global Accord with Novartis.....II-103
Sanofi-Aventis and Astellas Pharma to Restructure their JV Operations in
  Japan.....II-103
1$100
   Biomira Amends its Agreements with Merck.....II-104
AstraZeneca Takes Over Canadian Biologics Plant.....II-104
Pfizer Acquires Coley Pharmaceutical Group.....II-104
Abraxis Takes Over Watson’s Manufacturing Facility.....II-104
1$100
   Abraxis Takes Over Pfizer’s Cruce Davila Manufacturing Facility.....II-105
Bristol-Myers Squibb Takes Over Adnexus Therapeutics.....II-105
Merck Partners with a Florida-based Research Center.....II-105
Organon Partners with Medarex.....II-105
1$100
   Genzyme Acquires Bioenvision.....II-106
Genentech Inks a Deal with Seattle Genetics.....II-106
TopoTarget Takes Over Apoxis.....II-106
Roche Acquires CuraGen’s Subsidiary.....II-106
GPC Biotech Inks an Agreement with Yakult.....II-106
MediGene Acquires Avidex.....II-106
1$100
   Sanofi-Aventis Inks an Agreement with Taiho.....II-107
Biogen Inks Merger Agreement with Conforma.....II-107
Roche Signs a Merger Agreement with Ventana.....II-107
1$100
   Roche Takes Over THP to Enhance Its Therapeutic Antibody Profile.....II-108
ImClone Systems and Merck Revise ERBITUX Agreement.....II-108
GSK Invests €500 Million in France.....II-108
Amgen Takes Over Avidia.....II-108
Moores Cancer Center Collaborates with Medarex.....II-108
1$100
   ADITUS Medical Forms an Alliance with IGEA.....II-109
Callisto Opens Site For Phase–II Clinical Trials of Atiprimod.....II-109
XOMA Inks an Agreement with Attenuon.....II-109
AstraZeneca Joins Schering to Develop a Novel Breast Cancer Drug.....II-109
1$100
   Nventa to Procure Hiltonol from Oncovir Incorporated.....II-110
MaxCyte and Medinet Sign an Agreement for Immuno-Cell Therapy.....II-110
Receptor Acquires Cancer Vaccine ‘G17DT’ from Aphton.....II-110
1$100
   Enzon Collaborates with Santaris for Joint Development of Novel RNA
  Antagonists.....II-111
Epeius Receives Funding from Lazarex for Rexin-G™ Trials.....II-111
Callisto Inks a Deal with M.D. Anderson Cancer Center.....II-111
1$100
   AstraZeneca Inks an Agreement with Abraxis BioScience.....II-112
diaDexus and BVF Establish CFD Therapeutics.....II-112
Merck Acquires US Rights for Liposome Vaccine.....II-112
1$100
   Genentech Enters Into Alliance with Inotek.....II-113
AstraZeneca Takes Over KuDOS Pharmaceuticals.....II-113
Genzyme Acquires AnorMED.....II-113
Genentech Collaborates with Accelerate Brain Cancer Cure.....II-113
1$100
   Sonus and Schering Enter into a Global Licensing Agreement.....II-114
Abgenix Inks Merger Agreement with Amgen.....II-114
1$100
   AstraZeneca and Astex Enter into an Alliance.....II-115
Pfizer Inks Global License Pact with Coley Pharmaceutical Group.....II-115
Genzyme Takes Over ILEX Oncology.....II-115
1$100
   Genentech and CGI Enter into an Exclusive Agreement.....II-1161$100
   Amgen, Inc. (USA).....II-117
Amgen’s Oncology Pipeline As of 2011.....II-117
1$100
   AstraZeneca PLC (UK).....II-118
AstraZeneca’s Cancer Drugs Under Pipeline as of 2011.....II-118
1$100
   Bayer Schering Pharma (Germany).....II-1191$100
   Bayer’s Oncology Pipeline (As of 2011).....II-120
Biogen Idec Inc (USA).....II-120
Bristol-Myers Squibb Company (USA).....II-120
1$100
   Celgene Corporation (USA).....II-121
Celgene’s Oncology Drug Pipeline (As of 2011).....II-121
Cell Therapeutics, Inc. (USA).....II-121
1$100
   Cell Therapeutics’ Oncology Pipeline (As of 2011).....II-122
Cephalon, Inc. (USA).....II-122
1$100
   Cephalon’s Oncology Pipeline (As of 2011).....II-123
Chugai Pharmaceutical Co., Ltd. (Japan).....II-123
1$100
   Chugai’s Oncology Drug Pipeline (As of 2011).....II-124
Eli Lilly and Company (USA).....II-124
1$100
   Lilly’s Oncology Drug Pipeline as of 2011.....II-1251$100
   Imclone Systems, Inc (USA).....II-1261$100
   F. Hoffmann-La Roche Ltd (Switzerland).....II-127
Select Mid- and Late- Stage Compounds in Roche’s Oncology Pipeline.....II-127
1$100
   Genentech, Inc. (USA).....II-1281$100
   Genzyme (USA).....II-129
Genzymes’ Oncology Drug Pipeline as of 2011.....II-129
GlaxoSmithKline (UK).....II-129
1$100
   GlaxoSmithKline’s Oncology Pipeline (As of 2011).....II-1301$100
   Janssen Biotech, Inc (USA).....II-131
Merck KGaA (Germany).....II-131
Merck Serono’s Oncology Pipeline (As of 2011).....II-131
1$100
   Novartis AG (Switzerland).....II-132
Novartis’ Oncology Drug Pipeline (As of 2011).....II-132
1$100
   OSI Pharmaceuticals, Inc. (USA).....II-133
OSI Pharmaceuticals’ Oncology Pipeline Status (As of 2011).....II-133
Pfizer (USA).....II-133
1$100
   Pfizer’s Oncology Drug Pipeline (As of 2011).....II-134
Sanofi-Aventis (France).....II-134
1$100
   Oncology Drug Pipeline of sanofi-aventis as of 2011.....II-1351$100
   Seattle Genetics, Inc. (USA).....II-136
Seattle’s Cancer Therapy Pipeline as of 2011.....II-136
Takeda Pharmaceutical Company Limited (Japan).....II-136
1$100
   Takeda’s Oncology Pipeline (As of 2011).....II-1371$100
   Table 24: Global Recent Past, Current & Future Analysis for Cancer Therapies by Geographic Region - US, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1381$350
   Table 25: Global Historic Review for Cancer Therapies by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1391$350
   Table 26: Global 15-Year Perspective for Cancer Therapies by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1401$350
   Analytics by Segment.....II-141
Table 27: Global Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-141
1$350
   Table 28: Global Historic Review for Immunotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1421$350
   Table 29: Global 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1431$350
   Table 30: Global Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1441$350
   Table 31: Global Historic Review for Targeted Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1451$350
   Table 32: Global 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1461$350
   Table 33: Global Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1471$350
   Table 34: Global Historic Review for Hormone Therapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1481$350
   Table 35: Global 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1491$350
   Table 36: Global Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-1501$350
   Table 37: Global Historic Review for Chemotherapy by Geographic Region - US, Japan, Europe and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1511$350
   Table 38: Global 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1521$350
   A. Market Analysis.....II-153
Current and Future Analysis.....II-153
Table 39: Sales of Select Leading Cancer Drugs in the US (2009 & 2010) (includes corresponding Graph/Chart).....II-153
1$350
   Recession Hits the Pharma Market, Oncology Area too Succumbs.....II-154
Medicare Restructures its Coverage for Chemotherapy.....II-154
Personalized Care for Cancer Treatment in US.....II-154
1$100
   Drugs in Development in the US – A Recent Past Scenario.....II-155
Chemotherapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007).....II-155
Hormonal Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007).....II-155
1$100
   Targeted Therapy Drugs Undergoing Trials for Breast Cancer Treatment in United States (as of 2007).....II-1561$100
   Statistical Findings.....II-157
Table 40: US Market for Hospital Cancer Therapies (2004 and 2010): Percentage Breakdown of Revenues by Treatment Type - Surgery, Chemotherapy Drugs, Radiation Therapy, Biotechnology-Based Drugs, and Others (includes corresponding Graph/Chart).....II-157

Table 41: US Demand for Chemotherapy Drugs (2004 and 2010): Percentage Breakdown of Revenues by Drug Class - Alkylating Agents & Related, Antimetabolites & Related, Mitotic Inhibitors, and Others (includes corresponding Graph/Chart).....II-157
1$350
   Table 42: US Market for Multiple Myeloma Therapeutics (2009): Percentage Breakdown of Revenues by Company - Celgene Corporation, Millennium Pharmaceuticals and Others (includes corresponding Graph/Chart).....II-158

Table 43: US Market for Breast Cancer Therapeutics (2010): Percentage Breakdown of Revenues by Segment: Targeted Therapeutics, Cytotoxic Therapeutics, and Hormonal Therapeutics, and (includes corresponding Graph/Chart).....II-158
1$350
   US Cancer Statistics.....II-159
Table 44: New Cancer Cases in the US by Affected Site: 2009 (includes corresponding Graph/Chart).....II-159
2$350
   Table 45: New Cancer Cases in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-1611$350
   Table 46: New Cancer Cases in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-1621$350
   Cancer Mortality Statistics.....II-163
Table 47: Cancer Related Deaths in the US By Affected Site: 2009 (includes corresponding Graph/Chart).....II-163
2$700
   Table 48: Cancer Related Deaths in Males in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-1651$350
   Table 49: Cancer Related Deaths in Females in US by Leading Site: 2009 (includes corresponding Graph/Chart).....II-166
New Drug Approvals.....II-166
2$350
   New Drug Launches.....II-1681$100
   Strategic Corporate Developments.....II-1694$295
   Focus on Select Major Players.....II-17310$395
   B. Market Analytics.....II-183
Table 50: The US Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-183
1$350
   Table 51: The US Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1841$350
   Table 52: The US 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1851$350
   A. Market Analysis.....II-186
Current and Future Analysis.....II-186
Focus on Select Major Players.....II-186
3$295
   B. Market Analytics.....II-189
Table 53: Japanese Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-189
1$350
   Table 54: Japanese Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-1901$350
   Table 55: Japanese 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-1911$350
   A. Market Analysis.....II-192
Current and Future Analysis.....II-192
Regional Perspective.....II-192
1$100
   Advancements in Breast Cancer Treatment in Europe.....II-193
New Formulations that are Under Clinical Trials.....II-193
Drugs Undergoing Trials for Bladder Cancer Treatment in Europe As of 2006.....II-193
1$100
   European Cancer Statistics.....II-194 1$100
   Table 56: Cancer Incidence in Europe by Site (2009) (includes corresponding Graph/Chart).....II-1951$350
   New Drug Approval.....II-196
New Drug Launch.....II-196
Strategic Corporate Developments.....II-196
3$295
   Focus on Select Major Players.....II-1999$495
   B. Market Analytics.....II-208
Table 57: European Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-208
1$350
   Table 58: European Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2091$350
   Table 59: European 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2101$350
   A. Market Analysis.....II-211
Current and Future Analysis.....II-211
Regional Market Overview.....II-211
Canada.....II-211
Table 60: Estimated New Cancer Cases by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart).....II-211
1$350
   Table 61: Estimated New Cancer Cases by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart).....II-212

Table 62: Estimated Cancer Deaths by Type/Site Among Canadian Men: 2010 (includes corresponding Graph/Chart).....II-212
1$350
   Table 63: Estimated Cancer Deaths by Type/Site Among Canadian Women: 2010 (includes corresponding Graph/Chart).....II-213
Asia.....II-213
Cancer Statistics in Asia-Pacific.....II-213
1$350
   Table 64: Cancer Incidence in Asia-Oceania by Site: 2009 (includes corresponding Graph/Chart).....II-214
Australia.....II-214
1$350
   India.....II-215
Korea.....II-215
Malaysia.....II-215
1$100
   Latin America.....II-216
Brazil.....II-216
Mexico.....II-216
Argentina.....II-216
New Drug Approvals.....II-216
1$100
   New Drug Launches.....II-2171$100
   Strategic Corporate Developments.....II-2183$295
   B. Market Analytics.....II-221
Table 65: Rest of World Recent Past, Current & Future Analysis for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart).....II-221
1$350
   Table 66: Rest of World Historic Review for Cancer Therapies by Segment - Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart).....II-2221$350
   Table 67: Rest of World 15-Year Perspective for Cancer Therapies by Segment - Percentage Breakdown of Dollar Sales for Immunotherapy, Targeted Therapy, Hormone Therapy, and Chemotherapy for Years 2003, 2010 & 2017 (includes corresponding Graph/Chart).....II-2231$350